4Sarid D, Ron IG, Sperber F, et al. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase Ⅱ study[J]. Clin Drug Investig,2006, 26(12) : 691 -701.
5Takada J, Katsuki Y, Hamada H, et al. Two cases of inoperable gastric cancer successively treated with TS-1 + CDDP as neoadjuvant chemotherapy [ J ]. Gan To Kagaku Ryoho, 2006, 33 ( 12 ) : 1897 - 1899.
6Hinnis AR, Luekett JC, Walker RA. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients[J]. Br J Cancer,2007, 96(4) : 639 -645.
7Okada E, Murai Y, Matsui K. Survivin expression in tumor cell nuclei is p redicative of a favorable prognosis in gastric cancer patients[J]. Cancer Lett, 2003, 163( 1 ) : 109 - 116.
8Lundberg BB, Risovic V, Ramaswamy M, et al. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration [ J ]. J Controlled Release, 2003, 86 ( 1 ) : 93 -100.
9Zhang XF, Li YX, Chen XS, et al. Synthesis and characterization of the paclitaxel/MPEG-PLA block copolymer conjugate [ J ]. Bio-materials, 2005, 26(14): 2121 -2128.
